Story thread · 3 reports / 3 sources
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
freemalaysiatoday.com · 2h
How the coverage leans
Across 3 sources · syndicated copies counted once
Investors are concerned about Novo Nordisk's long-term sales growth as the clock ticks down on patent protection.
First report: Novo investors call for dealmaking and new drugs — ft.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.